• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

byRavi Shah, MD MBA
July 28, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability to reduce the number of gadolinium enhancing lesions on MRI imaging.

2. Key clinical outcomes of annualized relapse rates or change in a disability score were not different between patients treated with placebo compared to evobrutinib at 24 weeks. 

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Multiple sclerosis (MS) is a progressive, demyelinating autoimmune disease that forms identifiable lesions in the central nervous system. Clinical goals of treatment are to reduce the frequency of relapse events and to slow disease progression. In addition to clinical measures of treatment efficacy, imaging findings of lesions in the central nervous system can be used as a proxy market for treatment efficacy. B cells involved in autoimmune disease are thought to play a role in MS, and thus augmenting their activity through the BTK signaling cascade may reduce their effect on MS disease progression. This phase 2 trial evaluated the BTK inhibitor evobrutinib compared to placebo and showed high doses of evobrutinib can significantly reduce the number of central nervous system lesions identified on MRI in MS patients, though clinical markers of disease progression were not altered with evobrutinib treatment at 24 weeks.

The strengths of this study include its evaluation of a novel therapy in a progressive disease, study of multiple dosing regimens, and use of dimethyl fumarate (DMF) as a reference therapy. The study is limited by the generalizability of the patient population, limited study size segmented into multiple treatment groups, and lack of comparison between the evobrutinib and DMF groups. Longer trials will be need to determine evobrutinib’s long term efficacy.

Click to read the study in NEJM

RELATED REPORTS

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bruton’s tyrosine kinase (BTK) inhibitorevobrutinibmultiple sclerosis
Previous Post

Quick Take: The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT)

Next Post

Differences in NICU quality and access leads to racial disparities in neonatal outcomes

RelatedReports

Chronic Disease

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

June 2, 2025
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

June 5, 2025
#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

May 30, 2025
#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

April 21, 2025
Next Post
Poverty, preterm birth demonstrate additive effect on cognition

Differences in NICU quality and access leads to racial disparities in neonatal outcomes

2 Minute Medicine Rewind July 29, 2019

2 Minute Medicine Rewind July 29, 2019

Quick Take: Short-course primaquine for the radical cure of Plasmodium vivax malaria

Quick Take: Short-course primaquine for the radical cure of Plasmodium vivax malaria

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Repeated medial branch blocks do not improve pain outcomes for thermal radiofrequency ablation
  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.